Compare Gilead Sciences, Inc. (GILD) vs Realty Income Corp (O) Price & Performance

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Realty Income (O) trades at $62.51, up 0.24% today, with a bearish technical signal from moving averages but bullish oscillators like RSI. The REIT reported Q2 2026 AFFO of $1.09 per share, matching estimates, and raised full-year guidance, supported by a 98.8% occupancy rate. Recent news highlights its high dividend yield and 115th consecutive quarterly increase, alongside a $6 billion data center joint venture announced in August 2026.

Outlook: Strong dividend growth and strategic expansion into data centers offer upside, but high P/E of 45.63 and recent EPS misses pose valuation risks. Analysts target $67.13 consensus, implying modest growth, with debt-to-asset ratio rising to 39.93% in 2025 signaling financial leverage concerns.